|By PR Newswire||
|April 19, 2014 02:00 AM EDT||
DALLAS, April 19, 2014 /PRNewswire/ --
ReportsnReports.com offers COPD Drug Market Opportunity & Clinical Pipeline Analysis 2014 to 2018 industry research report in its store at http://www.reportsnreports.com/reports/280894-copd-drug-market-opportunity-clinical-pipeline-analysis.html .
The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018. Some of the drugs which are major contributors to this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. By 2018, it is expected that the combinations of LABA/LAMA would the leading drugs driving sales in the COPD therapy market and by 2021, these drugs would account for more than 25% of the market share. While in 2013, close to 50% of the global market was accounted by the US, with the other regions together accounting for 50%. However, it is expected that by 2018, the share of the USA would reduce marginally to 45%, while the lost share of this region would be taken over by the Asian region.
Companies discussed in COPD Drug Market Opportunity & Clinical Pipeline Analysis research report include Almirall, AstraZeneca, Boehringer Ingelheim, Bayer, Chiesi Farmaceutici, Forest Laboratories, Lallemand Pharma, Merck & Co, Novartis and Sunovion Pharmaceuticals. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=280894 .
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli. These disorders have become one of the major reasons for disability and death. The prevalence and incidence of this disease is increasing worldwide.
Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. Inspite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease. There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler.
ThisCOPD Drug Market Opportunity & Clinical Pipeline Analysis Report Highlights:
• COPD Drug Market Overview
• COPD Patient Base: Global, US & Europe
• FDA & EMA Guidelines on Clinical Investigation of COPD Drugs
• COPD Drug Clinical Pipeline by Phase & Country
• COPD Drug in Development Phase: 174
• Majority of COPD Drugs in Preclinical Phase: 72
• Marketed COPD Drugs: 36
• Discontinued & Suspended COPD Drug Profiles
Other newly published reports on the pharmaceuticals industry available with us:
China Pharmaceutical Distribution Industry Report, 2013 market research says thanks to the continuous advancement in new medical reform, China's pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of roughly 20% in 2005-2013. Companies discussed in this report include China National Accord Medicines, Nanjing Pharmaceutical Co., Ltd (NPC), Chongqing Tongjunge, Shanghai No.1 Pharmacy, China National Medicines, Huadong Medicine, Cachet, Jointown, Realcan Pharmaceutical¸ Shanghai Pharma, Zhejiang Int'l Group, Zhejiang Zhenyuan and CNPIC. Complete report is available at http://www.reportsnreports.com/reports/280794-china-pharmaceutical-distribution-industry-report-2013.html .
Market Research Report on Global and Chinese Benzarone Industry, 2009-2019 is a professional and in-depth market survey on global and Chinese benzarone markets. This report provides forecasts information on 2014-2019 Global and China Capacity, Production, and Production Value of Benzarone, 2014-2019 Benzarone Industry Cost and Profit Estimation, 2014-2019 Global and China Market Share of Benzarone, 2014-2019 Global and China Supply and Consumption of Benzarone and 2014-2019 China Import and Export of Benzarone. Complete report is available at http://www.reportsnreports.com/reports/280193-market-research-report-on-global-and-chinese-benzarone-industry-2009-2019.html .
List of Figures provided in COPD Drug Market Opportunity & Clinical Pipeline Analysis research report include:
Figure 1-1: Global - People Suffering With COPD (Million), 2013-2018
Figure 1-2: US - People Suffering With COPD (Million), 2013-2018
Figure 1-3: US - People Suffering With COPD by Age Group (%)
Figure 1-4: Europe - People Suffering With COPD (Million), 2013-2018
Figure 1-5: Europe - Death from COPD ('000) , 2005 & 2030
Figure 1-6: Global COPD Drug Market (US$ Billion), 2012-2018
Figure 1-7: Number of COPD Drugs in Clinical Trial by Phase, 2014
Figure 1-8: COPD Drugs in Clinical Trial by Phase (%), 2014
Figure 1-9: Number of Discontinued COPD Drugs in Clinical Trial by Phase, 2014
Figure 1-10: Discontinued COPD Drugs in Clinical Trial by Phase (%), 2014
Figure 1-11: Number of Suspended COPD Drugs in Clinical Trial by Phase, 2014
Figure 1-12: Suspended COPD Drugs in Clinical Trial by Phase (%), 2014
Figure 1-13: Number of No Development in COPD Drugs in Clinical Trial by Phase, 2014
Figure 1-14: No Development in COPD Drugs in Clinical Trial by Phase (%), 2014
ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on:
Oct. 22, 2016 09:30 PM EDT Reads: 9,651
Oct. 22, 2016 09:00 PM EDT Reads: 2,244
Oct. 22, 2016 09:00 PM EDT Reads: 1,250
Oct. 22, 2016 09:00 PM EDT Reads: 3,889
Oct. 22, 2016 08:45 PM EDT Reads: 2,004
Oct. 22, 2016 08:45 PM EDT Reads: 2,469
Oct. 22, 2016 08:45 PM EDT Reads: 848
Oct. 22, 2016 08:15 PM EDT Reads: 678
Oct. 22, 2016 08:15 PM EDT Reads: 3,779
Oct. 22, 2016 07:45 PM EDT Reads: 1,820
Oct. 22, 2016 07:00 PM EDT Reads: 770
Oct. 22, 2016 06:45 PM EDT Reads: 626
Oct. 22, 2016 06:00 PM EDT Reads: 8,964
Oct. 22, 2016 05:30 PM EDT Reads: 491